Monovision and multifocal IOLs offer excellent refractive outcomes

Article

Monovision correction and multifocal IOLs work well for correcting distance vision, with multifocal IOLs reducing the need for glasses but significantly increasing dysphotopsia for those who underwent implantation.

Monovision correction and multifocal IOLs work well for correcting distance vision, with multifocal IOLs reducing the need for glasses but significantly increasing dysphotopsia for those who underwent implantation. That’s the conclusion of research recently published in the Journal of Cataract & Refractive Surgery.

Investigators from Greece conducted a prospective randomized trial of 75 participants who had a diagnosis of senile cataract with stage 2 nuclear opalescence. Thirty-eight were assigned to the monovision group, and 37 were assigned to the multifocal IOL group. The researchers assessed uncorrected distance visual acuity (UDVA) and corrected distance visual acuity as well as Visual Function Index-14 (VF-14) scores and spectacle dependence, before surgery and 6 months afterward.

"Both techniques provided excellent refractive outcomes in UDVA and VF-14 scores," the researchers reported. Participants in the monovision group, however, demonstrated a greater need for glasses for near vision but experienced less glare than those in the multifocal group.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.